T3 Therapy: The Complete Guide for Chronic Illness Recovery

T3 therapy is one of the most underused tools in chronic illness recovery. Standard thyroid replacement, which prescribes T4 (levothyroxine) and titrates to TSH normalization, fails for a substantial subset of chronically ill patients because the problem is not glandular output. The problem is tissue-level conversion and utilization of T3, and giving more T4 to a patient whose conversion machinery is impaired often makes the condition measurably worse.

This guide explains the mechanism behind tissue-level thyroid resistance, why slow-release T3 (SR-T3) addresses it where standard thyroid replacement does not, the temperature-guided dosing protocol that calibrates therapy without requiring lab access, and why T3 is the cellular electricity that the Scorch Protocol's other phases require to work.

You will learn:

• Why "normal" thyroid labs (TSH, free T4) can coexist with profound tissue-level T3 deficiency
• The four mechanisms behind tissue-level thyroid resistance (transport, conversion, receptor, metabolic diversion)
• Why T4 supplementation can actively worsen the condition it appears to treat
• The slow-release T3 protocol: gradual climb, temperature-guided endpoint, mandatory taper
• The clinical case for T3 as the "relaxation molecule" and the first domino in chronic illness recovery
• How T3 therapy interacts with dry fasting, refeeding, and hGH in the full Scorch Protocol arc
• Sourcing, dosing, monitoring, and safety considerations

This guide focuses on T3 therapy specifically. The full Scorch Protocol context is in the Long Covid Recovery guide, the dry fasting complete guide, and the ME/CFS Recovery guide.

What T3 Actually Does

T3 (triiodothyronine) is the active form of thyroid hormone. It binds to nuclear thyroid hormone receptors on virtually every cell in the body and to dedicated receptors on the mitochondrial inner membrane, where it directly regulates mitochondrial supercomplex organization and ATP synthesis efficiency (Cioffi et al., 2022 — T3 enhances mitochondrial supercomplex organization and ATP synthesis, Cells). T3 is the master regulator of cellular metabolic rate.

T4 (thyroxine) is a storage form. T4 itself has minimal direct cellular activity; it must be converted to T3 by the DIO2 enzyme (primarily in the liver and locally in other tissues) before it can drive cellular metabolism. The TSH and free T4 levels that standard thyroid testing measures reflect the availability of T4 in the bloodstream, which is necessary but not sufficient for adequate cellular T3 activity.

For most of the general population with adequate metabolic health, the standard testing paradigm works: low T4 indicates a problem, T4 supplementation restores the bloodstream supply, and the conversion machinery produces enough T3 to meet the cells' needs.

For chronically ill patients, this paradigm breaks down at the conversion and tissue-utilization layers. The standard tests do not measure the layers that are failing.

Why "Normal Labs" Can Coexist with Profound T3 Deficiency

Standard blood tests measure circulating thyroid hormone. They do not measure:

• Whether T3 is entering cells (transporter function)
• Whether T3 is binding nuclear receptors (receptor sensitivity)
• Whether the T4-to-T3 conversion is producing active T3 or diverting toward reverse T3
• Whether mitochondrial T3 receptors are activating ATP production

A chronically ill patient can have "normal" TSH and "normal" free T3 and still be in profound tissue-level T3 deficiency. The mechanisms include:

DIO2 impaired conversion. The DIO2 Thr92Ala genetic variant impairs peripheral T4-to-T3 conversion. Carriers can appear "normal" on standard labs while peripheral tissues are functionally T3-deficient. A 300-patient randomized controlled trial in The Lancet (Panicker et al., 2009) showed that T4+T3 combination therapy produced significantly better cognitive outcomes than T4 alone, with effect concentrated in DIO2 variant carriers.

Metabolic diversion to reverse T3. Under metabolic stress, T4 is preferentially diverted toward reverse T3 (rT3) production rather than active T3. rT3 does not function as a competitive receptor blocker (the old "rT3 blocks the receptor" framing is mechanistically incorrect, per Halsall & Oddy, 2021 — rT3 has 200-fold lower nuclear receptor binding affinity than T3 and functions as metabolic diversion rather than receptor blockade, Annals of Clinical Biochemistry). The mechanism is that T4 is being shunted away from T3 production, starving the cell.

Transporter dysfunction. The MCT8 and MCT10 transporters carry T3 across the cell membrane. Genetic variants and acquired transporter dysfunction reduce intracellular T3 delivery even when blood T3 levels are adequate.

Receptor downregulation. Chronic inflammation downregulates thyroid receptor sensitivity. Cells stop responding even when T3 is present.

The "biofilm-like" cellular wall resistance. Beyond the well-characterized mechanisms, severely chronically ill patients clinically respond to aggressive T3 flooding even when none of the above is the dominant explanation. The mechanism is not fully mapped by current science but appears to be a membrane-level resistance that requires cellular T3 supply to be elevated substantially above standard physiological levels to overcome.

Why T4 Supplementation Can Make You Worse

This is the part most chronically ill patients on T4 therapy do not know.

When DIO2 conversion is impaired or cellular metabolic stress is already diverting T4 metabolism toward rT3, prescribing more T4 does not just fail to help. It actively increases the rT3 pool. The patient ends up with higher rT3 than before treatment, compounding the metabolic diversion. The chronically ill patient on levothyroxine often feels worse on the medication than before it, even when TSH normalizes.

This is the specific mechanism by which standard thyroid therapy makes a substantial subset of Long Covid, ME/CFS, and chronic Lyme patients measurably worse. The lab values look better. The patient feels worse. The conversation usually ends with the physician concluding the medication is "working" because TSH is normal and the patient must be misattributing their symptoms.

The patient is not misattributing. The medication is producing exactly the metabolic effect the mechanism predicts. T4 therapy in a body that cannot convert it is therapeutic for healthy patients, harmful for chronically ill patients with impaired conversion machinery.

What Slow-Release T3 Does Differently

Slow-release T3 (SR-T3) bypasses the conversion problem entirely. The medication is liothyronine (T3) compounded in a sustained-release formulation that delivers a steady, gradually rising tissue T3 level rather than the sharp peak-and-crash of immediate-release T3.

Immediate-release T3 has a half-life of approximately 1-1.4 days (Colucci et al., 2013 — liothyronine half-life 1.0-1.4 days versus T4 half-life 6-7 days). Standard immediate-release dosing produces a peak at 2-4 hours followed by a decline. In adrenal-fatigued patients (which describes most of the chronic illness cohort), this peak-and-crash pattern triggers cortisol spikes followed by adrenaline crashes that make the medication difficult to tolerate at therapeutic doses.

SR-T3 produces a flat pharmacokinetic curve with Tmax at approximately 4.4 hours and minimal serum T3 variation between doses (Mehran et al., 2023 — SR-T3 produces flat pharmacokinetic curve vs immediate-release T3 sharp peak then rapid decline). The steady tissue exposure is what makes high therapeutic doses tolerable in patients who would crash on immediate-release T3 at the same total daily dose.

T3 as the "Relaxation Molecule"

A useful clinical framing: T3 is the body's most powerful relaxation agent, because it solves the root cause of cellular tension at scale.

The mechanism: muscle relaxation requires ATP. The SERCA pump that pulls calcium out of muscle cells (allowing them to relax after contraction) is ATP-dependent. Without sufficient ATP, calcium stays in the cell, the muscle cannot relax, and rigidity sets in. Rigor mortis is the ultimate expression of this mechanism (when cellular ATP reaches zero, the muscle is permanently contracted until tissue breakdown releases the cross-bridges).

In chronic illness, this mechanism operates at a lower intensity but across every muscle and every cell. Cellular ATP is chronically low. Cells cannot fully relax. The patient experiences this as stiffness, tension, the inability to wind down, the wired-but-tired pattern.

T3 drives mitochondrial ATP production. Restoring tissue-level T3 activity restores cellular ATP supply, which restores SERCA function, which restores muscle relaxation. The patient feels their body unclench in ways that meditation, CBD, and other relaxation modalities have not produced because the underlying problem was energy supply, not nervous system dysregulation.

This framing also explains why T3 opens the appetite window: increased cellular energy allows the body to relax, which allows appetite to return (Ishii et al., 2008 — T3 injection increased food intake within 2 hours via 169-278% increase in hypothalamic AMPK activity). For chronically ill patients with suppressed appetite, this opens the caloric window required for the refeeding phase of the protocol.

The 30-Day T3 Cycle Protocol

The standard T3 cycle in the Scorch Protocol runs approximately 30 days and follows three phases: gradual climb, peak hold, mandatory taper.

Gradual Climb (Days 1-15)

Start at a low dose (typically 12.5-25 mcg SR-T3 daily, split into morning and afternoon doses) and increase by 12.5-25 mcg every 3-5 days, tracking basal body temperature, resting heart rate, and symptom response at each step.

The climb is gradual for two reasons: safety (rapid T3 elevation stresses the cardiovascular system) and calibration (the therapeutic dose is unknowable in advance and can only be found by titrating to temperature response).

There is no fixed "therapeutic dose." The endpoint is average basal body temperature stabilizing at or above 98.6°F. Different patients reach this at different doses. The typical range is 60-150 mcg SR-T3 per day, with some patients requiring up to 250 mcg.

Peak Hold (Days 15-25)

Once basal body temperature is at or above 98.6°F average, hold the dose for 7-10 days while the body adapts to the restored cellular T3 supply. This is where the metabolic foundation that the protocol's other phases require gets established.

Mandatory Taper (Days 25-30+)

T3 has a short half-life. Dropping it abruptly leaves the patient with near-zero circulating thyroid hormone until the pituitary recovers (TSH recovery typically takes 12 ± 4 days, full HPT axis 16 ± 5 days; Jonklaas et al., 2015 — quantifies post-cessation HPT recovery timeline).

Taper by 12.5-25 mcg every 3-5 days. Many patients add a desiccated thyroid bridge (Armour Thyroid, NP Thyroid) during the taper to provide a gradual T4 source as the HPT axis reboots, smoothing the transition. Desiccated thyroid contains both T3 and T4 in physiologic ratios and is generally better tolerated than levothyroxine alone in this transition.

After a successful cycle, the patient should have measurable improvement in basal body temperature, reduced fatigue, and a higher caloric tolerance window. Different patients push to different levels per cycle; multiple cycles are expected for severely depleted patients.

Why Genetic Testing Is Not Required

A reasonable question: should you get DIO2 genetic testing before starting T3 therapy? The clinical answer is no, for two reasons.

First, the decision to use T3 therapy is made from symptoms and temperature, not from carrier status. A DIO2 variant carrier would start T3 regardless of whether the genetic test confirmed it. A non-carrier with the same clinical presentation would also benefit from T3, because the mechanisms beyond DIO2 conversion (transporter dysfunction, receptor downregulation, metabolic diversion) are not detected by DIO2 testing.

Second, 99% of chronically ill patients lack access to consistent medical testing. The protocol is designed for self-administration with basal body temperature as the primary objective endpoint. Temperature-guided SR-T3 dosing in CFS was validated prospectively in Friedman et al., 2006 without genetic testing, lab values, or clinician supervision required for the dosing decisions.

Track temperature daily, track symptoms, track functional capacity. That gives you the information you need.

Safety, Contraindications, and Monitoring

T3 therapy at the doses used in the Scorch Protocol is generally well-tolerated when implemented correctly. The contraindications and safety considerations:

Absolute contraindications:

• Untreated adrenal insufficiency (Addison's disease) — T3 increases cortisol demand
• Recent myocardial infarction or unstable angina
• Untreated hyperthyroidism
• Severe untreated arrhythmias

Relative contraindications and required precautions:

• Atrial fibrillation history (T3 can increase AFib risk; Gluvic et al., 2021 — AFib risk up to 15% in overt hyperthyroidism, dose-dependent). Cardiac monitoring is recommended above 150 mcg/day.
• Osteoporosis risk in postmenopausal women — long-term high-dose T3 can accelerate bone loss
• Pregnancy and breastfeeding — discuss with prescribing physician

Monitoring during the cycle:

• Daily morning basal body temperature (oral, before getting out of bed)
• Daily resting heart rate
• Weekly check-in on symptoms and functional capacity
• Above 150 mcg/day: more frequent cardiovascular monitoring (consider periodic ECG if AFib history)

Reassurance from the safety data: a 30-day study at supraphysiologic T3 levels (serum T3 421 ng/dL) in healthy volunteers showed no acute cardiovascular changes (Chen et al., 2022). The cardiac concerns are dose-dependent and concentrated at much higher doses than the typical therapeutic range.

Sourcing SR-T3

Slow-release T3 is compounded by specialized pharmacies. It is not a standard pharmacy stock medication. The list of pharmacies page covers sourcing options. The general considerations:

• Compounding pharmacies experienced with SR-T3 (chronic-illness.st is the most established source for the Scorch Protocol's specific formulation)
• Prescription required (T3 is a controlled medication in most jurisdictions)
• Common prescriber types: integrative medicine physicians, Wilson's Temperature Syndrome-familiar endocrinologists, telehealth services specializing in optimization medicine

The prescribing physician relationship matters substantially. T3 dosing differs from standard endocrinology practice (most endocrinologists are trained to suppress TSH only, not to titrate to temperature). A physician unfamiliar with the temperature-guided framework may not feel comfortable with the protocol dosing range.

Where T3 Fits in the Full Scorch Protocol Arc

T3 therapy is Phase 2 of the four-phase Scorch Protocol recovery sequence:

1. Phase 1: Dry fasting clears the viral and inflammatory load that suppressed the thyroid set-point in the first place
2. Phase 2: T3 therapy restores cellular electricity and reopens the caloric window
3. Phase 3: Refeeding plus hGH rebuilds what years of low energy depleted
4. Phase 4: Rotation cycles back into dry fasting plus T3 maintenance

T3 is not optional in this protocol because the caloric window for Phase 3 cannot open without it. You can eat all the food you want, but if your cells cannot receive and use it because the metabolic machinery is down, the calories will be stored as fat without producing the energy or repair you need. T3 is what makes the cellular machinery available.

T3 is also not sufficient on its own for most chronically ill patients. The full protocol arc is what produces sustained recovery.

Frequently Asked Questions

What if my doctor will not prescribe T3?

The standard endocrinology practice is to prescribe T4 alone and titrate to TSH. Many endocrinologists are not familiar with the Wilson's Temperature Syndrome framework or with SR-T3 compounding. Options: seek out an integrative medicine physician, a Wilson's-familiar endocrinologist, or a telehealth service specializing in thyroid optimization. The list of pharmacies page covers practical sourcing.

Can I do this with regular T3 (immediate-release) instead of SR-T3?

Immediate-release T3 can be made to approximate the SR-T3 curve by dosing 4 times per day in equal split doses, but the practical compliance is difficult and the spike-crash pattern is harder to manage. SR-T3 is meaningfully better for the chronic illness cohort.

What is the "Wilson's Temperature Syndrome" framework?

Dr. Denis Wilson developed the framework of using basal body temperature as the primary endpoint for T3 therapy and applying high-dose T3 cycles to restore the temperature set-point. The framework is the foundation of the dosing approach used in the Scorch Protocol. The specific application to chronic illness is in the Wilson's Temperature Syndrome treatment cluster.

Can I do this if my TSH is already suppressed from previous thyroid medication?

Yes, with care. A suppressed TSH from previous T4 therapy indicates the HPT axis is already in a partial recovery state. The T3 cycle still applies; the taper at the end may need to be longer to allow full HPT recovery.

What about pregnancy?

Pregnancy management of thyroid is specialized and beyond the scope of this guide. Discuss with a maternal-fetal medicine specialist familiar with both pregnancy thyroid management and the underlying chronic illness.

Where to Start

T3 therapy is Phase 2 of the Scorch Protocol. Most patients should not enter T3 therapy first; the standard sequence is Phase 1 (preparation and first dry fast) → Phase 2 (T3) → Phase 3 (refeeding and hGH). The exceptions are patients with severe metabolic depletion who cannot tolerate fasting on their current baseline; those patients may start with T3 to build the foundation that makes fasting safe later.

Read the T3 therapy protocol page for the practical execution, then the Long Covid Basics page or the ME/CFS Recovery guide for the full protocol context.